1. Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China;
2. Beijing Institute for Brain Disorders, Beijing 100069, China;
3. China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
Abstract：Parkinson's disease (PD) is a common neurodegenerative disorder. The clinical symptoms involve motor syndromes, such as bradykinesia, tremor, rigidity and gait disturbance, and non-motor syndromes, such as olfactory dysfunction, depression and constipation. The mechanism is still unknown. According to the classic pathology, it is the degeneration of dopaminergic neuron and Lewy body. However, this cannot explain all the manifestations. The studies of PD see a great progress in recent years. Our review focuses mainly on the biomarker, brain network and neuromodulation in PD.
[1] Kang J H, Mollenhauer B, Coffey C S, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease:The Parkin-son's Progression Markers Initiative study[J]. Acta Neuropathol, 2016, 131(6):935-949.
[2] Marques T M, Kuiperij H B, Bruinsma I B, et al. MicroRNAs in cere-brospinal fluid as potential biomarkers for Parkinson's disease and mul-tiple system atrophy[J]. Molecular Neurobiology, 2016:1-10.
[3] Shi M, Liu C, Cook T J, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease[J]. Acta neuropatho-logica, 2014, 128(5):639-650.
[4] Devic I, Hwang H J, Edgar J S, et al. Salivary α-synuclein and DJ-1:potential biomarkers for Parkinson's disease[J]. Brain, 2011, 134(7):e178-e178.
[5] Del Tredici K, Hawkes C H, Ghebremedhin E, et al. Lewy pathology in the submandibular gland of individuals with incidental Lewy body dis-ease and sporadic Parkinson's disease[J]. Acta neuropathologica, 2010,119(6):703-713.
[6] Cersósimo M G, Perandones C, Micheli F E, et al. Alpha-synuclein im-munoreactivity in minor salivary gland biopsies of Parkinson's disease patients[J]. Movement Disorders, 2011, 26(1):188-190.
[7] Wang N, Gibbons C H, Lafo J, et al. α-Synuclein in cutaneous auto-nomic nerves[J]. Neurology, 2013, 81(18):1604-1610.
[8] Donadio V, Incensi A, Leta V, et al. Skin nerve α-synuclein deposits a biomarker for idiopathic Parkinson disease[J]. Neurology, 2014, 82(15):1362-1369.
[9] Helmich R C, Hallett M, Deuschl G, et al. Cerebral causes and conse-quences of parkinsonian resting tremor:A tale of two circuits?[J]. Brain, 2012, 135(11):3206-3226.
[10] Mure H, Hirano S, Tang C C, et al. Parkinson's disease tremor-re-lated metabolic network:Characterization, progression, and treatment effects[J]. Neuroimage. 2011, 54(2):1244-53.
[11] Chen H M, Wang Z J, Fang J P, et al. Different Patterns of spontane-ous brain activity between tremor-dominant and postural Instability/gait difficulty subtypes of Parkinson's disease:A resting-state fMRI Study[J]. CNS Neuroscience & Therapeutics, 2015, 21(10):855-866.
[12] Alam M, Schwabe K, Krauss J K. The pedunculopontine nucleus area:critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation[J]. Brain, 2011, 134(1):11-23.
[13] Michely J, Volz L J, Barbe M T, et al. Dopaminergic modulation of mo-tor network dynamics in Parkinson's disease[J]. Brain, 2015:138(Pt 3):664-78.
[14] Málly J. Non-invasive brain stimulation (rTMS and tDCS) in patients with aphasia:Mode of action at the cellular level[J]. Brain research bulletin, 2013, 98:30-35.
[15] Kamble N, Netravathi M, Pal P K. Therapeutic applications of repeti-tive transcranial magnetic stimulation(rTMS) in movement disorders:A review[J]. Parkinsonism & Related Disorders, 2014, 20(7):695-707.
[16] Shukla A W, Shuster J J, Chung J W, et al. Repetitive transcranial magnetic stimulation(rTMS) therapy in Parkinson disease:A metaanalysis[J]. PM&R, 2016, 8(4):356-366.
[17] Arias P, Vivas J, Grieve K L, et al. Double-blind, randomized, place-bo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease[J]. Sleep Medicine, 2010, 11(8):759-765.
[18] Nosko D, Ferraye M U, Fraix V, et al. Low-frequency versus high-fre-quency stimulation of the pedunculopontine nucleus area in Parkin-son's disease:a randomised controlled trial[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2014:86(6):674-679.
[19] Velasco F, Llanos S, Avila-Rodriguez M A, et al. Metabolic changes induced by electrical stimulation of prelemniscal radiations for the treatment of parkinson disease[J]. Stereotactic and Functional Neuro-surgery, 2015, 93(5):333-341.
2017, Vol. 35 
